Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKromek Regulatory News (KMK)

Share Price Information for Kromek (KMK)

Share Price is delayed by 15 minutes
Get Live Data
8.25    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.50 (6.25%)
Market Cap: £54.06m
KMK Live PriceLast checked at - London Stock Exchange

Intraday Kromek Share Chart

Trading Update

1 May 2018 07:00

RNS Number : 6624M
Kromek Group PLC
01 May 2018
 

1 May 2018

 

Kromek Group plc

("Kromek" or the "Company" or the "Group")

 

Trading Update

 

Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, provides the following update on trading for the year ended 30 April 2018 ahead of its full year results to be issued in July 2018.

 

During the period, Kromek saw growth in sales through executing on its previously-signed agreements as well as commencing delivering on new high-value contracts won during the year. As a result, the Company expects to report revenue growth for the full year and achieve EBITDA breakeven, in-line with market expectations.

 

The Group's products continue to gain traction in all its business segments from the increasing adoption of CZT-based technology and other products. The Group expects to continue to win new customers and, together with the momentum of contract wins, it expects continued growth in the new financial year.

 

 

For further information, please contact:

 

Kromek Group plc

Arnab Basu, CEO

Derek Bulmer, CFO

 

+44 (0)1740 626 060

Cenkos Securities plc (Nominated Adviser and Joint Broker)

Max Hartley (NOMAD)

Julian Morse (Sales)

 

+44 (0)20 7397 8900

Cantor Fitzgerald Europe (Joint Broker)

Philip Davies

Will Goode

 

+44 (0)20 7894 7000

Luther Pendragon Ltd (PR)

Harry Chathli

Claire Norbury

Alexis Gore

+44 (0)20 7618 9100

 

About Kromek Group plc

 

Kromek Group plc is a UK technology Group (global HQ in County Durham) and a leading developer of high performance radiation detection products based on cadmium zinc telluride ("CZT") and other advanced technologies. Using its core technology platforms, Kromek designs, develops and produces x-ray and gamma ray imaging and radiation detection products for the medical, security screening and nuclear markets.

 

The Group's products provide high resolution information on material composition and structure and are used in multiple applications, ranging from the identification of cancerous tissues to hazardous materials, such as explosives, and the analysis of radioactive materials.

 

The Group's business model provides a vertically integrated technology offering to customers, from radiation detector materials to finished products or detectors, including software, electronics and application specific integrated circuits ("ASICs").

 

The Group has operations in the UK and US (California and Pennsylvania), and is selling internationally through a combination of distributors and direct OEM sales.

 

Currently, the Group has over one hundred full time employees across its global operations. Further information on Kromek Group is available at www.kromek.com and https://twitter.com/kromekgroup.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTIMMBTMBTJTMP
Date   Source Headline
5th Feb 20247:00 amRNSKromek granted £1.3m under Horizon Europe scheme
30th Jan 20247:00 amRNSInterim Results
25th Jan 20247:00 amRNSKromek receives £1.4m CBRN order for EU stockpile
23rd Jan 20247:00 amRNSNotice of Results
18th Jan 20247:00 amRNSKromek receives $1.6m in advanced imaging orders
7th Nov 20237:00 amRNSCollaboration agreement with new CT partner
31st Oct 20237:00 amRNSKromek receives additional $1m in CBRN orders
26th Oct 20237:00 amRNSFirst US DHS Contract for Biosecurity for $5.9m
9th Oct 20234:59 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSHolding(s) in Company
28th Sep 202311:25 amRNSResult of AGM
28th Sep 20237:00 amRNSFinancing Update
14th Sep 20237:00 amRNSPartial Conversion of Convertible Loan Notes
12th Sep 20237:00 amRNSKromek detectors in new Spectrum Dynamics scanner
1st Sep 20235:00 pmRNSNotice of AGM and Publication of Annual Report
24th Jul 20237:01 amRNSFinal Results
24th Jul 20237:00 amRNSAppointment of Joint Broker
5th Jun 20237:00 amRNSNew $1.5m CBRN contract in Asia
31st May 20239:05 amRNSHolding(s) in Company
25th May 20232:48 pmRNSResult of Open Offer, General Meeting and TVR
10th May 20231:39 pmRNSNotice of Investor Webinar
5th May 20233:46 pmRNSPlacing, Subscription, Open Offer and Notice of GM
2nd May 20237:00 amRNSKromek receives medical imaging order of c.$1.4m
19th Apr 20237:00 amRNSKromek and Analogic Collaboration Agreement
18th Apr 20237:01 amRNSTrading Update
18th Apr 20237:00 amRNSSeven-Year Agreement with Tier 1 OEM
29th Mar 20237:00 amRNSKromek secures orders totalling over $1m
22nd Mar 20232:51 pmRNSHolding(s) in Company
31st Jan 20237:00 amRNSInterim Results
31st Jan 20237:00 amRNSKromek awarded c. £2.5m by Innovate UK
9th Jan 20237:00 amRNSKromek Secures $0.8m Order for D3S ID
19th Dec 20227:00 amRNSFurther agreement with Smiths Detection
15th Dec 20229:32 amEQSKromek Group 'delighted' with new contracts
12th Dec 20227:00 amRNSKromek wins £1.5m in nuclear security contracts
16th Nov 20227:00 amRNSAward of £5m bio-threat contract by UK Government
10th Nov 20227:00 amRNSKromek awarded US nuclear security contract
17th Oct 202211:42 amRNSKromek detectors used in digital SPECT/CT scanner
28th Sep 202212:27 pmRNSResult of AGM
2nd Sep 20225:26 pmRNSNotice of AGM and Publication of Annual Report
23rd Aug 202211:10 amRNSFundraising of £1.14 million
5th Aug 20227:00 amRNSFundraising of £1.7m
3rd Aug 20222:05 pmRNSSecond Price Monitoring Extn
3rd Aug 20222:00 pmRNSPrice Monitoring Extension
2nd Aug 20227:00 amRNSFinal Results
2nd Aug 20227:00 amRNSKromek wins over $750k in new orders
7th Jul 20227:00 amRNSKromek enters agreement with Smiths Detection Inc.
25th May 20227:00 amRNSNew Nuclear Security order from US federal entity
16th May 202212:07 pmRNSDirector Share Purchase
16th May 20227:00 amRNSBusiness and Trading Update
16th May 20227:00 amRNSAppointment of Nominated Adviser and Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.